Santos G W, Saral R, Burns W H, Braine H G, Sensenbrenner L L, Wingard J R, Yeager A M, Jones R, Ambinder R F, Rowley S D
Johns Hopkins Hospital, Oncology Center, Baltimore, Md.
Acta Haematol. 1987;78 Suppl 1:175-80. doi: 10.1159/000205926.
Allogeneic bone marrow transplants (BMT) in acute lymphoblastic leukemia following cyclophosphamide (Cy) and total body irradiation (TBI) has resulted in disease-free survival (DFS) for CR1, CR2, and CR3 of 10/18 (56%), 16/30 (53%) and 4/17 (24%), respectively. Median follow-up of survivors was 25-43 months. One relapse was seen in CR1, 1 in CR2, and 6 in CR3. Allogeneic BMT in acute nonlymphoblastic leukemia (ANLL) following busulfan (Bu) resulted in DFS for CR1, CR2 + CR3 + early relapse of 21/47 (45%) and 13/41 (32%), respectively. Median DFS of survivors of all groups together was 36 months. DFS of all patients 20 years or less was 15/27 (56%) and 19/61 (31%) for ages 21-46. Three relapses of 47 (6%) were seen in CR1 and 6/41 (15%) in subsequent remission and early relapse. BMT of autologous BMT with 4-hydroperoxy-cyclophosphamide (4-HC) purged marrow in ANLL in CR1 (5), CR2 (32) and CR3 (9) following Bu + Cy resulted in DFS of 19/46 (41%) for 1-67 months (median 15 months). Twenty patients with prior risk non-Hodgkin's lymphoma received 4-HC-purged marrow following Cy + TBI. DFS was 10/20 (50%) for 1.4-9.5 years (median 2.9 years).
在环磷酰胺（Cy）和全身照射（TBI）后进行的急性淋巴细胞白血病异基因骨髓移植（BMT），对于首次完全缓解（CR1）、第二次完全缓解（CR2）和第三次完全缓解（CR3）患者的无病生存率（DFS）分别为10/18（56%）、16/30（53%）和4/17（24%）。幸存者的中位随访时间为25至43个月。CR1中有1例复发，CR2中有1例复发，CR3中有6例复发。在白消安（Bu）治疗后进行的急性非淋巴细胞白血病（ANLL）异基因BMT，CR1患者的DFS为21/47（45%），CR2 + CR3 +早期复发患者的DFS为13/41（32%）。所有组幸存者的中位DFS为36个月。20岁及以下所有患者的DFS为15/27（56%），21至46岁患者的DFS为19/61（31%）。CR1的47例患者中有3例复发（6%），后续缓解和早期复发的41例患者中有6例复发（15%）。在Bu + Cy后，对处于CR1（5例）、CR2（32例）和CR3（9例）的ANLL患者进行自体BMT，采用4-氢过氧环磷酰胺（4-HC）净化骨髓，1至67个月（中位15个月）的DFS为19/46（41%）。20例具有先前风险的非霍奇金淋巴瘤患者在Cy + TBI后接受了4-HC净化骨髓治疗。1.4至9.5年（中位2.9年）的DFS为10/20（50%）。
